NeuroSense Therapeutics Faces Nasdaq Delisting

CAMBRIDGE, Mass., June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. NRSN, a biopharmaceutical company actively engaged in the development of new treatments targeting serious neurodegenerative conditions, has been served a delisting notification by the Nasdaq Stock Market. This notice was issued upon the company's failure to meet the continuing listing standards as mandated by Nasdaq's marketplace rules.

NeuroSense's Stance and Course of Action

Upon receipt of the delisting letter, NeuroSense intends to formally appeal the decision, seeking to maintain its position on the market. The company believes it has viable grounds for the appeal and is preparing to present its case to the hearings panel. The timeframe set for the appeal process grants NeuroSense a temporary stay, during which its shares will continue to trade on Nasdaq under the ticker symbol NRSN.

Market Reaction and Shareholder Impact

While the news has inevitably stirred concern among the investor community, NeuroSense reassures its shareholders of its commitment to compliance and transparent communication throughout the appeal process. NeuroSense remains dedicated to advancing its therapeutic portfolio and ultimately seeking to restore its compliance with Nasdaq's listing standards.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. NeuroSense undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

delisting, appeal, biopharmaceutical